Source Count: 0 | Weighted Score: 0 | Source Confidence: [1/5] | Primary Tier: 2–3 | Last Updated: March 10, 2026
Keywords: bioethics, human enhancement, transhumanism, genetic enhancement, cognitive enhancement, doping, CRISPR, designer babies, nootropics, neuroenhancement, therapy vs enhancement, posthumanism, moral enhancement, biohacking, equity of access, informed consent
Category Tags: medicine, bioethics, enhancement, transhumanism, philosophy
Cross-References: X_4_02 — Medical Ethics · X_4_01 — Personalized Genomic Medicine · X_4_08 — Disability and Prosthetics · ZE_1_01 — Ethics

QUICK SUMMARY

The bioethics of enhancement addresses the moral, social, and philosophical questions raised by using medical and technological interventions not merely to treat disease or restore function, but to augment normal human capacities beyond species-typical norms. The therapy-enhancement distinction is the foundational conceptual boundary: therapy (fixing what is broken) is generally accepted; enhancement (making the normal better) is contested. This boundary, however, is neither philosophically clear nor practically enforceable. Historical precedent: humans have always sought to enhance their capabilities — caffeine, eyeglasses, nutritional supplements, and education are all "enhancements" of baseline human function; what has changed is the power and specificity of available technologies. Categories of enhancement: (1) Cognitive enhancement — pharmaceuticals (modafinil, methylphenidate/Ritalin, amphetamines) used by healthy individuals to improve focus, memory, or productivity; surveys suggest 5–35% of college students have used prescription stimulants non-medically (McCabe et al., 2014); the effectiveness of nootropics for healthy individuals is debated — effects tend to be modest and variable; (2) Physical enhancement — performance-enhancing drugs (EPO, anabolic steroids, growth hormone) in athletics; gene doping (using gene therapy techniques to enhance athletic performance) is banned by WADA but remains a theoretical concern; prosthetic enhancement raising questions about competitive fairness (Oscar Pistorius, running blade debate); (3) Genetic enhancement — the possibility of selecting or editing genes to enhance traits in future children; He Jiankui's CRISPR editing of twin embryos (November 2018, creating the first gene-edited babies — to confer resistance to HIV via CCR5 modification) was universally condemned by the scientific community as reckless, premature, and unethical — He was sentenced to three years in prison by a Chinese court (2019); the case highlighted the gap between technical capability and ethical governance; germline editing for enhancement (intelligence, appearance, athletic ability) remains hypothetical but raises profound questions about eugenics, inequality, and human identity; (4) Lifespan extension — anti-aging research (caloric restriction, senolytics, rapamycin, metformin, NAD+ precursors, telomere manipulation) seeks to extend healthy lifespan (healthspan) beyond current limits; whether aging is a "disease" to be treated or a natural process to be accepted is a philosophical and scientific debate. Philosophical positions: Transhumanism (Bostrom, More) — the view that human enhancement is morally permissible and potentially obligatory, that humans should use technology to transcend biological limitations; bioconservatism (Fukuyama, Kass, Sandel) — the view that human enhancement threatens human dignity, undermines the meaning of achievement, exacerbates inequality, and represents hubris; Michael Sandel's The Case Against Perfection argues that enhancement erodes the moral significance of "giftedness" — the appreciation of human capacities as given rather than manufactured; John Harris (proponent) argues that if enhancement makes people's lives go better, there is a moral obligation to pursue it. Regulatory landscape: no comprehensive international framework governs human enhancement; existing regulations address specific technologies (WADA for athletic doping, national laws on genetic modification, pharmaceutical regulation of cognitive drugs); the Oviedo Convention (1997) prohibits germline modification in signatory states but has limited global reach; the pace of technological development consistently outstrips regulatory response.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Scholarly Consensus)

1.1 He Jiankui CRISPR Baby Case

• The birth of CRISPR-edited twins (Lulu and Nana, November 2018) and a third gene-edited baby (born later) is confirmed through He Jiankui's public announcement, university investigation, and Chinese court conviction (2019); the scientific community's near-universal condemnation is documented through statements from the National Academies, WHO, and major scientific journals; independent analysis suggests the gene editing was poorly executed, with off-target effects and mosaicism, and that the CCR5 modification provided questionable medical benefit relative to the risks

1.2 Non-Medical Stimulant Use Prevalence

• Surveys documenting non-medical use of prescription stimulants among college students and professionals are published in peer-reviewed journals (McCabe et al., Addiction, 2014; Maier et al., Pharmacology, 2013); prevalence varies by population, survey method, and definition but is consistently reported in the 5–35% range among college students; the cognitive benefits for healthy individuals are modest in clinical trials and the long-term risks of non-prescribed use are incompletely understood

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Therapy-Enhancement Distinction

• The therapy-enhancement distinction — while practically useful — is philosophically unstable; the boundaries of "normal" function are culturally and historically variable; conditions once considered normal (e.g., short stature, mild cognitive limitation) are increasingly treated medically; some bioethicists (Daniels, Norm of Functioning; Powers et al.) have attempted to ground the distinction in species-typical functioning, but this has been criticized as arbitrary (what counts as species-typical changes over time) and as discriminatory (defining some bodies as "abnormal"); the debate is active and unresolved in bioethics literature

2.2 Anti-Aging Research Status

• Research on interventions that extend lifespan or healthspan (caloric restriction — established in model organisms from yeast to primates; senolytics — drugs that selectively eliminate senescent cells; metformin — the TAME trial [Targeting Aging with Metformin] is the first clinical trial of an anti-aging drug in humans, ongoing) is scientifically legitimate; however, whether any intervention can meaningfully extend healthy human lifespan beyond current maximums (~120 years) is unknown; the field is characterized by both genuine science and speculative commercial ventures

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Genetic Enhancement of Intelligence

• The genetic architecture of intelligence is polygenic (thousands of genetic variants each contributing small effects — most recent GWAS: Okbay et al., Nature Genetics, 2022, identified >3,000 variants); the prospect of polygenic embryo selection for intelligence (selecting embryos based on polygenic scores) is technically feasible but currently offers minimal predicted advantage (estimated 2.5 IQ point gain through selection among 10 embryos — Turley et al., Cell, 2021); future capabilities may increase but the ethical, social, and biological barriers are enormous; whether societies will permit or prohibit such technologies is unpredictable

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 "Limitless" Nootropic Drugs

• DEBUNKED The concept popularized by the film Limitless (2011) — a single pill conferring dramatic cognitive enhancement — has no basis in pharmacological reality; existing cognitive enhancement drugs (modafinil, methylphenidate, caffeine) produce modest effects on alertness and focus in specific tasks, not transformative intelligence augmentation; there is no evidence that any substance can significantly increase general intelligence (IQ) in healthy adults; marketing of nootropic supplements (racetams, alpha-GPC, various herbal combinations) typically relies on mechanistic plausibility and underpowered studies rather than rigorous clinical evidence

Counter-Arguments

• The enhancement debate is inseparable from inequality — if cognitive or physical enhancements become available, they will initially be accessible primarily to the wealthy, potentially creating a new kind of biological class system; proponents argue this concern applies equally to education, nutrition, and healthcare, which society already provides unequally without prohibiting them; opponents argue that genetic or neurological enhancement creates more durable and heritable advantage than existing inequalities
• The concept of "natural" human capacity is itself culturally constructed — humans in modern societies already live dramatically enhanced lives compared to pre-agricultural ancestors (nutrition, education, sanitation, medical care all "enhance" baseline function); the objection to enhancement as "unnatural" faces the challenge that the natural/artificial boundary has been continuously transgressed throughout human history
• Sport provides a concrete arena where enhancement debates play out — the fact that caffeine, altitude training, and specialized nutrition are permitted while EPO, anabolic steroids, and gene doping are banned reveals the arbitrariness of the "natural" performance boundary; the anti-doping regime (WADA) has been criticized both as insufficient (widespread evasion) and as overly punitive (criminalizing athletes for engaging in practices not fundamentally different from legal performance optimization)

IMAGES

No images assigned yet.

BIBLIOGRAPHY

• Sandel, M.J. The Case Against Perfection. Belknap/Harvard UP (2007).
• Bostrom, N. & Savulescu, J., eds. Human Enhancement. Oxford UP (2009). DOI: 10.1093/oso/9780199299720.001.0001
• Harris, J. Enhancing Evolution. Princeton UP (2007).
• Fukuyama, F. Our Posthuman Future. Farrar, Straus and Giroux (2002). DOI: 10.1086/377813
• Regalado, A. "Chinese Scientist Who Gene-Edited Babies Is Jailed for Three Years." MIT Technology Review (2019).
• McCabe, S.E. et al. "Medical and Nonmedical Use of Prescription Opioids Among US High School and College-Age Adults." Drug and Alcohol Dependence 142 (2014): 263–270. DOI: 10.1016/j.drugalcdep.2014.02.393
• Okbay, A. et al. "Polygenic Prediction of Educational Attainment Within and Between Families." Nature Genetics 54 (2022): 437–449.
• Turley, P. et al. "Problems with Using Polygenic Scores to Select Embryos." NEJM 385 (2021): 78–86. DOI: 10.1056/nejmsr2105065
• President's Council on Bioethics. Beyond Therapy. Dana Press (2003).
• Juengst, E.T. & Moseley, D. "Human Enhancement." Stanford Encyclopedia of Philosophy (2019).

CROSS-REFERENCE INDEX

Last Updated: March 10, 2026